Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of ALLN-177 in Subjects with Enteric or Primary Hyperoxaluria and Hyperoxalemia
2017-003547-38Phase 2Completed
- Sponsor
- Allena Pharmaceuticals, Inc.
- Start
- Apr 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of reloxaliase in absorptive hyperoxaluria, Primary hyperoxaluria (PH) and Not applicable, sponsored by Allena Pharmaceuticals, Inc. Primary endpoints: Reduction in plasma oxalate levels and Reduction in urinary oxalate levels. Started Apr 2018; status: completed.
02
Drugs
reloxaliase
03
Conditions
absorptive hyperoxaluriaPrimary hyperoxaluria (PH)Not applicable
Beyond the preview
Go deeper on 2017-003547-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003547-38.